Protein engineering of a fibroblast growth factor 2 protein for targeting to bone mineral hydroxyapatite.
The engineering of a novel FGF2 fused with highly conserved bone mineral-binding domain of osteocalcin (OC) for targeting to bone mineral hydroxyapatite (HA) exhibited much stronger HA-binding affinity than native FGF2. FGF2-OC also showed a significant increase of mitogenic activity and cellular differentiation of osteoblastic cells compared with native FGF2.
Jeon
Eunyi
E
Department of Biochemistry, Inha University School of Medicine, Incheon, Korea.
Jang
Jun-Hyeog
JH
D000469:Alkaline Phosphatase / Q000187:drug effects; D000818:Animals; D001842:Bone and Bones / Q000737:chemistry; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D017886:Durapatite / Q000378:metabolism*; D004926:Escherichia coli / Q000235:genetics; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D051379:Mice; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D015202:Protein Engineering / Q000379:methods*; D017434:Protein Structure, Tertiary / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology
D011993:Recombinant Fusion Proteins; D016222:Fibroblast Growth Factor 2; D015675:Osteocalcin; D017886:Durapatite; D000469:Alkaline Phosphatase